R&D News | pharmaphorum

News

OrbiMed raises $4.3bn for latest biotech funds

International healthcare investment group OrbiMed has raised around $4.3 billion in committed financing for distribution across three new private funds that will be used t

News

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

CAR-T therapies have transformed the treatment of some haematological cancers, but haven’t made much headway for solid tumours – although BioNTech thinks it may have the k

News

ESMO: Survival data mars Pluvicto prostate cancer trial

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistan

News

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Amid all the new high-tech therapies on display at the ESMO cancer conference, a study funded by Cancer Research UK has shown what can be achieved with cheap generic drugs

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

ESMO: Immunotherapy combos extend lives in bladder cancer

In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.

OrbiMed raises $4.3bn for latest biotech funds

ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours?

ESMO: Survival data mars Pluvicto prostate cancer trial

ESMO: Trials end 20-year hiatus in cervical cancer therapy

Rumour confirmed as Roche buys Telavant for $7.1bn

ESMO: Immunotherapy combos extend lives in bladder cancer

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks